Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Completed · Phase 2
Conditions studied: Liver Cancer
In brief
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab, erlotinib, and sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab together with erlotinib is more effective than giving sorafenib in treating patients with liver cancer. PURPOSE: This randomized phase II trial is studying how well giving bevacizumab together with erlotinib works compared with sorafenib as first-line therapy in treating patients with advanced liver cancer.
Key facts
- Study ID
- NCT00881751
- Run by
- Medical University of South Carolina
- People needed
- 95
- Starts
- 2009-03-01
- Expected to finish
- 2017-02-01
- Last updated by the study team
- 2017-09-11
Who can join
Age: 18 and older, up to 116. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
- California Pacific Medical Center — San Francisco, California, United States
- Columbia University/ New York Presbyterian Hospital — New York, New York, United States
- Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina, United States
- Tennessee Oncology, PLLCat Sarah Cannon Cancer Center — Nashville, Tennessee, United States
- UVA Cancer Center — Charlottesville, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.